share_log

Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?

Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?

經濟學家賈斯汀·沃爾費斯指出,奧茲派克和維格維的推動使肥胖率下降,創造了歷史性的肥胖問題轉變——美國已經到達轉折點嗎?
Benzinga ·  22:46

The United States may have reached a turning point in its decades-long battle against obesity. Recent data suggests that 2020 could mark the year when obesity rates in America not only peaked but began to decline, echoing the historic moment in 1963 when cigarette sales in the U.S. hit their apex before falling.

美國可能已經在幾十年來與肥胖作鬥爭的歷史中達到了一個轉折點。最近的數據表明,2020年可能是美國肥胖率不僅達到峯值,而且開始下降的一年,這一歷史時刻在1963年重現,當時美國的香菸銷售量達到頂峯後開始下降。

What Happened: Renowned economist Justin Wolfers highlighted this significant shift on social media platform X, stating, "From the Department of Things Really Are Getting Better: The U.S. obesity rate may have peaked, and for the first time in a long time, it fell last year." Wolfers attributes this change to new weight loss drugs, adding, "Chalk up another one to progress."

發生了什麼:著名經濟學家賈斯汀·沃爾弗斯在社交媒體平台X上突出了這一重大轉變,稱"從事情真的正在變好的角度看:美國的肥胖率可能已經達到頂峯,而且長時間以來首次去年有所下降。"沃爾弗斯將這一變化歸因於新的減肥藥物,並補充說"再得益於進步。"

John Burn-Murdoch, writing an opinion piece for the Financial Times, suggests that one in eight U.S. adults have used these drugs, with 6% currently taking them.

約翰·伯恩-默多克在《金融時報》撰寫的一篇評論文章中指出,八分之一的美國成年人使用了這些藥物,目前有6%正在使用。

The potential catalyst for this unprecedented decline? A new generation of diabetes and weight loss drugs, including Ozempic and Wegovy. These medications, which have shown remarkable results in clinical trials, are now being used by a significant portion of the U.S. population.

導致這一空前下降的潛在催化劑?一代新的糖尿病和減肥藥物,包括歐澤匹和維嘉。這些藥物在臨床試驗中取得了顯著的效果,現在被美國大部分人口大量使用。

As the U.S. leads this potential obesity decline, other countries are likely to follow suit. In Denmark, home to Novo Nordisk (NYSE:NVO), the creator of Ozempic and Wegovy, 3% of adults were using these drugs by the end of 2023, coinciding with a slowdown in obesity rate increases.

隨着美國引領這一潛在的肥胖率下降,其他國家可能會效仿。在丹麥,諾和諾德(NYSE:NVO)所在地,歐澤匹和維嘉的創建者,到2023年底,3%的成年人正在使用這些藥物,與肥胖率增加放緩相吻合。

From the Department of Things Really Are Getting Better: The U.S. obesity rate may have peaked, and for the first time in a long time, it fell last year.
And yes, it's the new weight loss drugs, which really work. Chalk up another one to progress. pic.twitter.com/icLjvfR57u

— Justin Wolfers (@JustinWolfers) October 5, 2024

發生了什麼:著名經濟學家賈斯汀·沃爾弗斯在社交媒體平台X上突出了這一重大轉變,稱"從事情真的正在變好的角度看:美國的肥胖率可能已經達到頂峯,而且長時間以來首次去年有所下降。"
而且,沒錯,是那些真正有效的新減肥藥物。再得益於進步。pic.twitter.com/icLjvfR57u

—賈斯汀·沃爾弗斯(@JustinWolfers),2024年10月5日

Why It Matters: The decline in obesity rates is significant in the context of recent developments in the pharmaceutical industry. Roche Holdings AG (OTC:RHHBY) has fast-tracked its obesity drug development, aiming for over $3 billion in sales potential. This move underscores the growing market for effective weight loss treatments.

爲何重要:肥胖率的下降在藥品行業最新發展背景下具有重要意義。羅氏控股AG(場外交易:羅氏)已經加速推進其肥胖藥開發,旨在實現超過30億美元的銷售潛力。這一舉措凸顯了對有效減肥治療的市場需求不斷增長。

Additionally, Eli Lilly and Co (NYSE:LLY) is exploring broader applications for its weight-loss drugs, Mounjaro and Zepbound, targeting individuals with a lower BMI.

此外,禮來(紐交所:LLY)正在探索其減肥藥Mounjaro和Zepbound的更廣泛應用,針對BMI較低的個體。

Despite the promising results, a recent study reveals a gap between clinical trial promises and real-world outcomes for drugs like Ozempic and Wegovy.

儘管有希望的結果,最近的研究揭示了臨床試驗承諾與類似Ozempic和Wegovy等藥物在現實世界中表現之間存在差距。

  • Boeing Workers' Union Says Decision To Cut Health Care For 33,000 Is 'Unnecessary And Cruel'
  • 波音工會表示裁減3.3萬人醫療保健福利的決定"不必要且殘忍"

Image Via Shutterstock

圖片來自Shutterstock。

This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote

本報道使用Benzinga Neuro生成,並由Kaustubh Bagalkote

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論